These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis? Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561 [TBL] [Abstract][Full Text] [Related]
30. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133 [TBL] [Abstract][Full Text] [Related]
31. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492 [TBL] [Abstract][Full Text] [Related]
32. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507 [TBL] [Abstract][Full Text] [Related]
33. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475 [TBL] [Abstract][Full Text] [Related]
34. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time. Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371 [TBL] [Abstract][Full Text] [Related]
36. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Verma S; Jensen D; Hart J; Mohanty SR Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360 [TBL] [Abstract][Full Text] [Related]
37. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis? Cengiz C; Ardicoglu Y; Bulut S; Boyacioglu S Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):813-9. PubMed ID: 19820404 [TBL] [Abstract][Full Text] [Related]
38. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Tasneem AA; Luck NH; Majid Z Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775 [TBL] [Abstract][Full Text] [Related]
39. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Akyuz U; Yesil A; Yilmaz Y Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973 [TBL] [Abstract][Full Text] [Related]
40. Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients. Billeter AT; Wloka S; Behnisch R; Albrecht T; Roessler S; Goeppert B; Mueller S; Nickel F; Müller B Obes Facts; 2021; 14(5):490-500. PubMed ID: 34419953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]